Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 12	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 17	JUL 28	CA/CAplus patent coverage enhanced
NEWS 18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20	JUL 28	STN Viewer performance improved
NEWS 21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 24	AUG 15	CAplus currency for Korean patents enhanced
NEWS 25	AUG 25	CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:32:56 ON 11 SEP 2008

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:33:18 ON 11 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 SEP 2008  HIGHEST RN 1048424-48-1
DICTIONARY FILE UPDATES:  10 SEP 2008  HIGHEST RN 1048424-48-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-553946genB.str
```



```
chain nodes :
```

```
4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20
ring nodes :
1  2  3
chain bonds :
2-4  3-6  4-5  4-17  6-7  6-18  7-8  8-9  8-12  9-10  10-11  10-20  12-13  13-14
14-15  15-16  15-19
ring bonds :
1-2  1-3  2-3
exact/norm bonds :
1-2  1-3  2-3  4-5  4-17  6-7  6-18  7-8
exact bonds :
2-4  3-6  8-9  8-12  9-10  10-11  10-20  12-13  13-14  14-15  15-16  15-19


Match level :
1:Atom  2:Atom  3:Atom  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
10:CLASS  11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS
18:CLASS  19:CLASS  20:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss full
FULL SEARCH INITIATED 14:35:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      434 TO ITERATE

100.0% PROCESSED      434 ITERATIONS                                19 ANSWERS
SEARCH TIME: 00.00.01

L2           19 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     179.74     179.95

FILE 'CAPLUS' ENTERED AT 14:35:41 ON 11 SEP 2008
```

FILE COVERS 1907 - 11 Sep 2008 VOL 149 ISS 11
FILE LAST UPDATED: 10 Sep 2008 (20080910/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3 4 L2

=> d l3 1-4 abs ibib hitstr

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AB The present invention relates to a method of using a therapeutically effective amount of at least one cathepsin B inhibitor for correcting bone mineralization defect. The invention also relates to a combination of the cathepsin B inhibitor with an other agent selected from the group of a second cathepsin B inhibitor, a PHEX polypoeptide, phosphate and calcitriol. Specifically, the invention discloses that the correction of bone miceralization defect includes an increase of d. of pure cortical bone, an increase of mean d. of tatal bone, an increase of cortical thickness , an increase of pure cortical area assigned to be cortical etc.

ACCESSION NUMBER: 2008:283346 CAPLUS
DOCUMENT NUMBER: 148:299923
TITLE: Methods of correcting bone mineralization defects by using cathepsin B inhibitors and the kits and compositions therefor
INVENTOR(S): Rowe, Peter; Yanagawa, Norimoto
PATENT ASSIGNEE(S): The University of Kansas, USA
SOURCE: Can. Pat. Appl., 80pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2558043	A1	20080224	CA 2006-2558043	20060824
AU 2006203680	A1	20080313	AU 2006-203680	20060824

PRIORITY APPLN. INFO.: CA 2006-2558043 T0 20060824
IT 791627-76-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods of correcting bone mineralization defects by using cathepsin B inhibitors and kits and compns. therefor)

RN 791627-76-4 CAPLUS

CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, ethyl ester, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AB Cathepsin K was originally identified as an osteoclast-specific lysosomal protease, the inhibitor of which has been considered might have therapeutic potential. We show that inhibition of cathepsin K could potently suppress autoimmune inflammation of the joints as well as osteoclastic bone resorption in autoimmune arthritis. Furthermore, cathepsin K-/- mice were resistant to exptl. autoimmune encephalomyelitis. Pharmacol. inhibition or targeted disruption of cathepsin K resulted in defective Toll-like receptor 9 signaling in dendritic cells in response to unmethylated CpG DNA, which in turn led to attenuated induction of T helper 17 cells, without affecting the antigen-presenting ability of dendritic cells. These results suggest that cathepsin K plays an important role in the immune system and may serve as a valid therapeutic target in autoimmune diseases.

ACCESSION NUMBER: 2008:126455 CAPLUS

DOCUMENT NUMBER: 148:306309

TITLE: Cathepsin K-Dependent Toll-Like Receptor 9 Signaling Revealed in Experimental Arthritis

AUTHOR(S): Asagiri, Masataka; Hirai, Toshitake; Kunigami, Toshihiro; Kamano, Shunya; Gober, Hans-Juergen; Okamoto, Kazuo; Nishikawa, Keizo; Latz, Eicke; Golenbock, Douglas T.; Aoki, Kazuhiro; Ohya, Keiichi; Imai, Yuuki; Morishita, Yasuyuki; Miyazono, Kohei; Kato, Shigeaki; Saftig, Paul; Takayanagi, Hiroshi

CORPORATE SOURCE: Department of Cell Signaling, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan

SOURCE: Science (Washington, DC, United States) (2008), 319(5863), 624-627
CODEN: SCIEAS; ISSN: 0036-8075

PUBLISHER: American Association for the Advancement of Science

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 221144-20-3, NC 2300
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cathepsin K-dependent Toll-Like receptor 9 signaling revealed in exptl. arthritis)

RN 221144-20-3 CAPLUS

CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, sodium salt (1:1), (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AB This invention is intended to purify (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid with the use of a salt from the carboxylic acid and an organic amine selected from among piperazine, adamantanamines, etc. and to provide crystalline sodium and potassium salts of the carboxylic acid which are enhanced in storage stability so as to be suitable for use as a raw material for medicinal drug. By this method, the title carboxylic acid was obtained in 99.9% purity.

ACCESSION NUMBER: 2004:965234 CAPLUS
DOCUMENT NUMBER: 141:410803
TITLE: Process for preparation of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid salts
INVENTOR(S): Tendo, Atsushi; Takahashi, Toshihiro; Yamakawa, Tomio; Okai, Kazuki; Nihashi, Susumu
PATENT ASSIGNEE(S): Nippon Chemiphar Co., Ltd., Japan
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096785	A1	20041111	WO 2004-JP5767	20040422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004234235	A1	20041111	AU 2004-234235	20040422
CA 2523233	A1	20041111	CA 2004-2523233	20040422
EP 1619190	A1	20060125	EP 2004-728921	20040422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1809549	A	20060726	CN 2004-80017044	20040422
US 20060252826	A1	20061109	US 2005-553946	20051021

IN 2005CN02749 A 20070601 IN 2005-CN2749 20051024
PRIORITY APPLN. INFO.: JP 2003-121103 A 20030425
WO 2004-JP5767 W 20040422

IT 777838-84-3P 791627-71-9P 791627-72-0P
791627-73-1P 791627-74-2P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid salts)

RN 777838-84-3 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 791627-71-9 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, (2S,3S)-, compd. with cyclohexanamine (1:1) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 108-91-8
CMF C6 H13 N



RN 791627-72-0 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, (2S,3S)-, compd. with N1,N2-bis(phenylmethyl)-1,2-ethanediamine (1:1) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 140-28-3
CMF C16 H20 N2



RN 791627-73-1 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-, (2S,3S)-3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]oxiranecarboxylate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 791627-74-2 CAPLUS
CN Lysine, mono[(2S,3S)-3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]oxiranecarboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 70-54-2
CMF C6 H14 N2 O2



IT 221144-20-3P 791627-75-3P 791627-77-5P
791627-78-6P 791627-79-7P 791627-80-0P
791627-81-1P 791627-82-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid salts)
RN 221144-20-3 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, sodium salt (1:1), (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 791627-75-3 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, potassium salt (1:1), (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



● K

RN 791627-77-5 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, (2S,3S)-, compd. with piperazine (1:1) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 110-85-0
CMF C4 H10 N2



RN 791627-78-6 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, (2S,3S)-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 768-94-5
CMF C10 H17 N



RN 791627-79-7 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, (2S,3S)-, compd. with tricyclo[3.3.1.13,7]decan-2-amine (1:1) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 13074-39-0
CMF C10 H17 N



RN 791627-80-0 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, (2S,3S)-, compd. with N-cyclohexylcyclohexanamine (1:1) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 101-83-7
CMF C12 H23 N



RN 791627-81-1 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, (2S,3S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 791627-82-2 CAPLUS
CN L-Arginine, mono[(2S,3S)-3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]oxiranecarboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 777838-84-3
CMF C14 H25 N O5

Absolute stereochemistry.



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2

Absolute stereochemistry.



IT 791627-76-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid salts)

RN 791627-76-4 CAPLUS

CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, ethyl ester, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

GI



I



II

AB Novel epoxysuccinamide derivs. (3-carboxyoxirane-2-carboxamides) represented by general formula (I) or physiol. acceptable salts thereof [wherein R1 and R3 are each H, alkyl, alkenyl, alkynyl, aryl, aralkyl, a heterocyclic group, or alkyl substituted with a heterocyclic group; R2 is alkyl, alkenyl, alkynyl, aryl, aralkyl, a heterocyclic group, or alkyl substituted with a heterocyclic group; X is O or NR4 (wherein R4 is H, alkyl, aryl, aralkyl, a heterocyclic group, or alkyl substituted with a heterocyclic group); Y1 is OR5, SR6 or NR7R8 (wherein R5, R6 and R7 are each H, alkyl, aryl, aralkyl, acyl, a heterocyclic group, or alkyl substituted with a heterocyclic group; and R8 is the same as defined as to R4); and Y2 is H or alkyl, or alternatively Y1 and Y2 may be united to form =O, =S, =N-R9 or =N-OR10 (wherein R9 and R10 are each the same as defined as to R4), with the proviso that the alkyl, aryl and heterocyclic groups defined as to R5 to R10 may each have one or more specific substituents and that the groups defined as to R1 to R10 and Y2 are each specified in the number of carbon atoms] are prepared These compds. inhibit bone absorption and activity of cathepsin L and B (cysteine protease) and are useful for the treatment of bone diseases such as osteoporosis, malignant hypercalcemia, and Paget's disease of bone, arthritis deformans and chronic articular rheumatism accompanied by unusual exasperation of cathepsin B and L activity, and muscular dystrophy and muscular atrophy related to cathepsin B and L. Thus, (2S,3S)-3-ethoxycarbonyloxirane-2-carboxylic acid was condensed with (S)-1-[(R)-α-methoxybenzyl]-3-methylbutylamine using N-hydroxysuccinimide and DCC in EtOAc at room temperature overnight to give the title compound (II). II at 15 mg/kg p.o. lowered

serum calcium by 20.4% in rat.

ACCESSION NUMBER: 1999:184251 CAPLUS
DOCUMENT NUMBER: 130:223163
TITLE: Preparation of epoxysuccinamide derivatives for treatment of bone diseases and arthritis
INVENTOR(S): Nomura, Yutaka; Takahashi, Toshihiro; Yoshino, Yasushi; Nishioka, Koichiro
PATENT ASSIGNEE(S): Nippon Chemiphar Co., Ltd., Japan
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911640	A1	19990311	WO 1998-JP3983	19980904
W: AU, CA, CN, JP, KR, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9889978	A	19990322	AU 1998-89978	19980904
EP 1022276	A1	20000726	EP 1998-941728	19980904
EP 1022276	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 241607	T	20030615	AT 1998-941728	19980904
EP 1342720	A2	20030910	EP 2003-11154	19980904
EP 1342720	A3	20040211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1022276	T	20031031	PT 1998-941728	19980904
ES 2201524	T3	20040316	ES 1998-941728	19980904
US 6387908	B1	20020514	US 2000-508026	20000505
US 20020091131	A1	20020711	US 2002-42994	20020108
US 6689785	B2	20040210		

PRIORITY APPLN. INFO.:
JP 1997-257538 A 19970904
EP 1998-941728 A3 19980904
WO 1998-JP3983 W 19980904
US 2000-508026 A3 20000505

OTHER SOURCE(S): MARPAT 130:223163
IT 221144-15-6P 221144-16-7P 221144-17-8P
221144-18-9P 221144-19-0P 221144-20-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of epoxysuccinamide derivs. as bone absorption inhibitors and cathepsin B and L inhibitors for treatment of bone diseases and arthritis)
RN 221144-15-6 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, 1-methylethyl ester, (2S,3S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 221144-16-7 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 221144-17-8 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, cyclohexyl ester, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 221144-18-9 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, phenyl ester, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 221144-19-0 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-

methylpropoxy)methyl]butyl]amino]carbonyl]-, 4-(1,1-dimethylethyl)phenyl ester, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 221144-20-3 CAPLUS
CN 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-, sodium salt (1:1), (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 14:37:42 ON 11 SEP 2008